CLIN2 Awards: Funding Opportunity for Clinical Trials
CLIN2 Awards: Funding Opportunity for Clinical Trials supports research organizations completing stem cell-based or genetic therapy trials to address serious unmet medical needs and advance patient benefit.
Browse similar grants
Funder: California Institute for Regenerative Medicine
Due Dates: October 23, 2026 (Mandatory consultation) | October 30, 2026, 2 PM PT (Application)
Funding Amounts: Up to $8 million, $12 million, or $15 million, depending on trial stage and applicant status; up to four years
Summary: Supports completion of clinical trials for stem cell-based and genetic therapies addressing serious unmet medical needs.
Key Information: The applicant organization or PI must be the IND sponsor, and every trial must include a California site.
Description
CIRM’s CLIN2 program supports completion of a single interventional phase 1, 2, or 3 clinical trial, including pivotal trials, for innovative stem cell-based or genetic therapies. Therapies should address serious unmet medical needs and offer potentially transformative benefits to patients, families, and the healthcare system. CIRM also provides internal expertise and access to external clinical development experts to advance funded projects.
The trial must sit within a comprehensive development strategy aimed at marketing approval, with stage-appropriate patient access and pre-commercialization planning. Projects should enroll participants reflective of the affected disease population and share data and knowledge to improve rigor, efficiency, and transparency. Associated natural history or healthy-volunteer lead-in studies may be supported when needed for the interventional trial.
